Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort.
Bettiol, A., Urban, M.L., Dagna, L., Cottin, V., Franceschini, F., Del Giacco, S., et al. (2021). Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study. ARTHRITIS & RHEUMATOLOGY [10.1002/art.41943].
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study
Bargagli, Elena;
2021-01-01
Abstract
Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort.File | Dimensione | Formato | |
---|---|---|---|
Mepolizumab for Eosinophilic Granulomatosis-Bettiol-2021.pdf
Open Access dal 06/08/2022
Descrizione: Articolo
Tipologia:
Post-print
Licenza:
Creative commons
Dimensione
1.97 MB
Formato
Adobe PDF
|
1.97 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1151441